ClinicalTrials.gg
CompletedNCT01234038NSCLCUpdated Jun 27, 2018

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

A Phase 1/2 interventional study of ISIS EIF4E Rx and ISIS EIF4E Rx in Non-small Cell Lung Cancer, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 29 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 24 under way, 5 of them phase 3. Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
52nd of 203
116 · median 50
Started
2010
with 4 others
Phase 1/2
24 of 221
1 open now
Registered
136th of 221
by date

Among the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 52nd largest by enrollment of the 203 interventional ones that give a count, is one of 5 that started in 2010, is one of 24 in phase 1/2, and was the 136th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies testing paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients age >/= 18 years
  • or cytologically confirmed diagnosis of NSCLC
  • Stage IV disease (including patients with pleural effusion who were previously classified as Stage IIIB)
  • All of the following if patient has had prior radiation therapy:

    1. Lesion(s) used for determination of response were not previously irradiated or have increased in size since the completion of radiotherapy
    2. The patient has recovered from any acute effects of the radiotherapy
    3. Radiotherapy was completed at least 4 weeks prior to Screening
  • Part 1: Have at least non-measurable evaluable disease (e.g., lesions which are smaller than the minimum size required for measurability; other non- such as bone , malignant pleural effusion)
  • Part 2: Have measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension
  • Performance status of 0 or 1 on the Performance Status Scale
  • Have an estimated of at least 12 weeks
  • Adequate organ function within 14 days prior to first study dose (ISIS EIF4E Rx or carboplatin/paclitaxel, whichever occurs first) as defined by:

    1. (ANC) >/= 1.5 x 109/L
    2. count >/= 100 x 109/L
    3. >/=9 g/dL (>/= 5.6 mmol/L). Patients may receive packed RBC transfusion to achieve this level at the discretion of the investigator.
    4. Total \< 1.5 x (ULN) unless elevated secondary to conditions such as Gilbert's Disease
    5. (AST) \< 3 x ULN (\< 5 x ULN in the presence of hepatic metastases)
    6. Alanine aminotransferase (ALT) \< 3 x ULN (\< 5 x ULN in the presence of hepatic metastases)
    7. Alkaline phosphatase \< 3.0 x ULN
    8. Calculated >/= 60 mL/min per Cockcroft and Gault formula
  • Satisfy one of the following:

    1. Females: non-pregnant and non-lactating; surgically sterile, , or patient or partner compliant with a reliable regimen, as determined by Investigator, for 4 weeks prior to Screening. Patients of must test negative for pregnancy at Screen and must agree to use a reliable method of birth control during the study and for the 10 weeks following the last dose of ISIS EIF4E Rx.
    2. Males: surgically sterile or patient or partner must agree to use a reliable contraceptive method, as determined by the Investigator during the study and for the 10 weeks following the last dose of ISIS EIF4E Rx.
  • For Part 1: have discontinued all prior chemotherapies, biological therapies, and other therapies for cancer for at least 4 weeks (6 weeks for mitomycin-C or nitrosoureas) prior to study treatment and recovered from the acute effects of therapy.

Exclusion criteria

Exclusion Criteria:

  • Part 1: More than 2 prior chemotherapy or biological therapy regimens (approved or experimental) for NSCLC, not counting and neoadjuvant treatment. A regimen is defined as two or more consecutive cycles of treatment.
  • Part 2: Any prior chemotherapy or biological therapy (approved or experimental) for NSCLC including adjuvant and neoadjuvant treatments
  • Treatment with another drug, biological agent, or device within 4 weeks (6 weeks for biological agents) before Screening or 5 half-lives of study agent, whichever is longer
  • Patients with treated or untreated parenchymal or . Brain imaging is required for symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
  • Patients with known pericardial effusion
  • Have active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator)
  • Presence or history of other than NSCLC, carcinoma in situ of the cervix, or non-melanoma skin cancer. In the case of other malignancies, patients may be considered for participation if the prior malignancies were diagnosed and definitively treated at least five years previously with no subsequent evidence of recurrence.
  • Presence of an underlying disease state associated with active bleeding
  • Ongoing therapy with oral or parenteral anticoagulants (e.g., heparin, warfarin/coumadin). Low-dose anticoagulants for maintenance of catheter patency and low dose aspirin (≤ 325 mg/day) and nonsteroidal anti-inflammatory agents are not exclusionary.
  • Concurrent treatment with other anticancer drugs
  • Pre-existing peripheral neuropathy >/= Version 4.0 (CTCAE) Grade 2
  • Known history of , , or chronic infection
  • Previous treatment with a therapeutic antisense oligonucleotide or siRNA
  • Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device
  • Have any other medical conditions that in the opinion of the Investigator, would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1

    Drug: ISIS EIF4E Rx · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Part 1 Cohort 2

    Drug: ISIS EIF4E Rx · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Part 2 Arm A

    Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Part 2 Arm B

    Drug: ISIS EIF4E Rx · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • DrugISIS EIF4E Rx

    800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle

  • DrugISIS EIF4E Rx

    1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle

  • DrugISIS EIF4E Rx

    (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle

  • 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle

  • AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: At the end of each 21 day cycle

07

Study locations

29 sites
  • Achieve Clinical Research
    Birmingham, Alabama 35216, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Little Rock Cancer Clinic
    Little Rock, Arkansas 72205, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Joliet Hematology Oncology Associates
    Joliet, Illinois 60435, United States
  • University of Louisville - James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Jewish Hospital & St. Mary's Healthcare
    Louisville, Kentucky 40245, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Koranyi National Institute of TBC and Pulmonology
    Budapest, H-1121, Hungary
  • Semmelweis University Faculty of Medicine
    Budapest, H-1125, Hungary
  • University of Debrecen, Medical and Health Science Center
    Debrecen, H-4032, Hungary
  • Hospital for Thoracic Diseases of Csongrad County Local Governmental
    Deszk, H-6772, Hungary
  • Bekes Country Pandy Kalman Hospital
    Gyula, H-5703, Hungary
  • K. Dluski Provincial Specialist Hospital
    Bialystok, 15-540, Poland
  • Independent Public Teaching Hospital No. 4 In Lublin
    Lublin, 20-954, Poland
  • Idependent Public Tuberculosis an Lung Diseases Facilities
    Olsztyn, 10-357, Poland
  • Specialist Tuberculosis and Lung Diseases Hospitals
    Rzeszow, 35-241, Poland
  • Alojzy Pawelec Provincial Hospital of Lung Diseases
    Wodzislaw Slaski, 44-300, Poland
  • State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Chemotherapy department
    Arkhangelsk, 163045, Russian Federation
  • State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Clinical Oncology Center, Chemotherapy Department
    Chelyabinsk, 454087, Russian Federation
  • State Budget Healthcare Institution: Sverdlovsk Regional Oncology Center, Radiotherapy Department
    Ekaterinburg, 620036, Russian Federation
  • State Healthcare Institution: Ivanovo Regional Oncology Center, Chemotherapy Department
    Ivanovo, 153013, Russian Federation
  • Non-State Medical Institution: Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC Russian Railways, Chemotherapy Dept.
    Moscow, 129128, Russian Federation
  • State Healthcare Institution: Leningrad Regional Clinical Hospital, Thoracic Surgery Department
    Saint Petersburg, 194291, Russian Federation
  • St. Petersburg State Healthcare Institution: "City Clinical Oncology Center"
    Saint Petersburg, 197022, Russian Federation
  • State Higher Educational Institution: St. Petersburg State Medica University n.a.I.P. Pavlov under the Federal Agency for Healthcare and Social Development, Pulmonology Research Institute
    Saint Petersburg, 197101, Russian Federation
  • State Institution: Samara Regional Clinical Oncology Center, Chemotherapy Department
    Samara, 443031, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Oct 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2010
First posted
Nov 4, 2010
Start
Nov 2010
Primary completionActual
Oct 2012
CompletionActual
Jan 2013
Results delay requested
Jun 21, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234038
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Nov 2010
Primary completion
Oct 2012
Completion
Jan 2013
Last update
Jun 27, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Carboplatin

Start the discussion